Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2741564 | 0.93 | AKR1C3 (0.39) | AKR1C3AKR1C2APPPDE3BPDE3A | |
| SCHEMBL20380670 | 0.92 | PTGS2 (0.34) | AKR1C3AKR1C2APPGPR3 | |
| SCHEMBL20380602 | 0.87 | AKR1C3 (0.32) | AKR1C3AKR1C2APPGPR3 | |
| SCHEMBL25808495 | 0.87 | ALOX5AP (0.39) | AKR1C3AKR1C2APPPDE3BPDE3A | |
| SCHEMBL17371157 | 0.86 | ALOX5AP (0.38) | AKR1C3AKR1C2APPPDE3BPDE3A | |
| SCHEMBL16866174 | 0.86 | AKR1C3 (0.37) | AKR1C3AKR1C2APPPDE3BPDE3A | |
| SCHEMBL17365763 | 0.85 | PTGS2 (0.33) | AKR1C3AKR1C2APP | |
| SCHEMBL18735548 | 0.85 | AKR1C3 (0.33) | AKR1C3AKR1C2APPPDE3BPDE3A | |
| SCHEMBL18887655 | 0.85 | PDE3B (0.33) | AKR1C3AKR1C2APPPDE3BPDE3A | |
| SCHEMBL20380675 | 0.84 | RPS6KA3 (0.35) | AKR1C3AKR1C2APPPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023799-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023799-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | PIEZO1, ROCK1, RCC1 | AKR1C3 3629/4885AKR1C2 3582/4885APP 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.